Prof. Dr. Murat Binbay'ın akademik çalışmaları — tam metinleri PDF olarak indirebilirsiniz.
The FDA has extended the perioperative approval of pembrolizumab plus enfortumab vedotin to all MIBC cystectomy candidates. KEYNOTE-B15/EV-304: EFS HR 0.53, OS HR 0.65.
The FDA has expanded the perioperative approval of EV plus pembrolizumab to all MIBC patients regardless of cisplatin eligibility. KEYNOTE-B15/EV-304: EFS HR 0.53, OS HR 0.65.
The FDA has approved adjuvant belzutifan plus pembrolizumab in ccRCC at intermediate-high/high risk of recurrence. LITESPARK-022: a 28% reduction in risk of recurrence or death (HR 0.72; p=0.0003).
The FDA has approved adjuvant belzutifan plus pembrolizumab in high-risk ccRCC after nephrectomy. LITESPARK-022: a 28% improvement in DFS (HR 0.72).
The FDA has approved belzutifan plus pembrolizumab as adjuvant treatment for ccRCC. LITESPARK-022: a 28% improvement in DFS, with 24-month DFS of 80.7% versus 73.7% (HR 0.72).
The FDA has approved capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC. CAPItello-281: median rPFS 33.2 months versus 25.7 months (HR 0.81).
The FDA has approved capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC. CAPItello-281: median rPFS 33.2 months versus 25.7 months (HR 0.81).
In the world's first vascularized bladder transplant, the patient voids spontaneously with a 600 mL capacity at six months and is fully continent, with no findings suggestive of rejection.
POTOMAC phase 3 trial: durvalumab plus BCG reduced the risk of recurrence or death by 32% (HR 0.68) in BCG-naive high-risk NMIBC. FDA approval on 28 May 2026.